Core Insights - Shanghai Minwei Biotech has licensed its self-developed GLP-1/GIP/FGF21 receptor triple agonist MWN105 injection to Denmark's Sidera Bio Aps, granting the latter global exclusive development and commercialization rights outside Greater China [1] - As part of the deal, Minwei Biotech will acquire a 9.99% equity stake in Sidera and receive a licensing fee [1] - Sidera will pay an initial investment and milestone payment of $35 million, with potential cumulative milestone payments not exceeding $1.01 billion based on clinical development and commercialization sales [1] - Minwei Biotech will also receive tiered sales royalties based on actual annual net sales [1] - This agreement is expected to enhance the global positioning of GLP-1 multi-target drugs, as the company aims to expand its overseas market through business development collaborations while balancing independent research and open cooperation to accelerate drug clinical transformation and market coverage [1]
民为生物：GLP-1/GIP/FGF21激动剂达成10.45亿美元海外授权合作